ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer

Journal of Surgical Oncology

Volumn 101, Issue 7, 2010, Pages 564-569

  Hong, Xin ^a,b   Michalski, Christoph W ^a   Kong, Bo ^a   Zhang, Weiwei ^a,c   Raggi, Matthias C ^a   Sauliunaite, Danguole ^a   De Oliveira, Tiago ^a   Friess, Helmut ^a   Kleeff, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SOUTHEAST UNIVERSITY   (China)

^c QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Adhesion; ALCAM; Chemoresistance; Invasion; Migration; Pancreatic cancer; Pancreatic endocrine tumors

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE;

ARTICLE; CANCER INVASION; CELL ADHESION; CELL FUNCTION; CELL GROWTH; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DISTANT METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROENDOCRINE TUMOR; PANCREAS CARCINOMA; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CELL ADHESION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952046397     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21538     Document Type: Article

References (35)

1. Baum B, Settleman J, Quinlan MP: Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008;19:294-308.
2. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-428.
3. Nair KS, Naidoo R, Chetty R: Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol 2005;58:343-351. (Pubitemid 40516162)
4. Swart GW: Activated leukocyte cell adhesion molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 2002;81:313-321.
5. Weiner JA, Koo SJ, Nicolas S, et al.: Axon fasciculation defects and retinal dysplasias in mice lacking the immunoglobulin superfamily adhesion molecule BEN/ALCAM/SC1. Mol Cell Neurosci 2004;27:59-69.
6. Gimferrer I, Calvo M, Mittelbrunn M, et al.: Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 2004;173:2262-2270.
7. Hassan NJ, Barclay AN, Brown MH: Frontline: Optimal T cell activation requires the engagement of CD6 and CD166. Eur J Immunol 2004;34:930-940.
8. Kato Y, Tanaka Y, Hayashi M, et al.: Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens. J Immunol 2006;177:877-884.
9. Zimmerman AW, Joosten B, Torensma R, et al.: Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006;107:3212-3220.
10. Ofori-Acquah SF, King JA: Activated leukocyte cell adhesion molecule: A new paradox in cancer. Transl Res 2008;151:122-128.
11. Degen WG, van Kempen LC, Gijzen EG, et al.: MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol 1998;152:805-813.
12. Kristiansen G, Pilarsky C,Wissmann C, et al.: ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003;54:34-43.
13. Kristiansen G, Pilarsky C, Wissmann C, et al.: Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005;205:359-376.
14. Weichert W, Knosel T, Bellach J, et al.: ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160-1164.
15. King JA, Ofori-Acquah SF, Stevens T, et al.: Activated leukocyte cell adhesion molecule in breast cancer: Prognostic indicator. Breast Cancer Res 2004;6:R478-R487.
16. Faca VM, Song KS,Wang H, et al.: A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008;5:e123.
17. Kleeff J, Michalski CW, Friess H, et al.: Surgical treatment of pancreatic cancer: The role of adjuvant and multimodal therapies. Eur J Surg Oncol 2007;33:817-823.
18. Kleeff J, Michalski C, Friess H, et al.: Pancreatic cancer: From bench to 5-year survival. Pancreas 2006;33:111-118.
19. Ehehalt F, Saeger HD, Schmidt CM, et al.: Neuroendocrine tumors of the pancreas. Oncologist 2009;14:456-467.
20. Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781.
21. Yao JC, Eisner MP, Leary C, et al.: Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-3500.
22. Friess H, Ding J, Kleeff J, et al.: Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003;60:1180-1199.
23. Abiatari I, Esposito I, De Oliveira T, et al.: Moesin dependent cytoskeleton remodeling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med 2009 May 11. [Epub ahead of print]
24. Bergmann F, Breinig M, Hopfner M, et al.: Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: Novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 2009;104:171-181.
25. Kleeff J, Kothari NH, Friess H, et al.: Adenovirus-mediated transfer of a truncated fibroblast growth factor (FGF) type I receptor blocks FGF-2 signaling in multiple pancreatic cancer cell lines. Pancreas 2004;28:25-30.
26. Michalski CW, Oti FE, Erkan M, et al.: Cannabinoids in pancreatic cancer: Correlation with survival and pain. Int J Cancer 2008;122:742-750.
27. Michalski CW, Autschbach F, Selvaggi F, et al.: Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease. Am J Surg 2007;193:476-481.
28. Michalski CW, Laukert T, Sauliunaite D, et al.: Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology 2007;132:1968-1978.
29. Michalski CW, Maier M, Erkan M, et al.: Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One 2008;3:e1701.
30. Michalski CW, Selvaggi F, Bartel M, et al.: Altered anti-inflammatory response of mononuclear cells to neuropeptide PACAP is associated with deregulation of NF-{kappa}B in chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol 2008;294:G50-57.
31. Zhi YH, Song MM, Wang PL, et al.: Suppression of matrix metalloproteinase-2 via RNA interference inhibits pancreatic carcinoma cell invasiveness and adhesion. World J Gastroenterol 2009;15:1072-1078.
32. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-252.
33. Stern R: Hyaluronidases in cancer biology. Semin Cancer Biol 2008;18:275-280.
34. Burkhardt M, Mayordomo E, Winzer KJ, et al.: Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 2006;59:403-409.
35. Jezierska A, Olszewski WP, Pietruszkiewicz J, et al.: Activated Leukocyte Cell Adhesion Molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit 2006;12:BR245-256.